1,146 results on '"Petrou, S"'
Search Results
2. Randomised controlled trial of analgesia for the management of acute severe pain from traumatic injury: study protocol for the paramedic analgesia comparing ketamine and morphine in trauma (PACKMaN)
- Author
-
Michelet, F., Smyth, M., Lall, R., Noordali, H., Starr, K., Berridge, L., Yeung, J., Fuller, G., Petrou, S., Walker, A., Mark, J., Canaway, A., Khan, K., and Perkins, G. D.
- Published
- 2023
- Full Text
- View/download PDF
3. Correction: An online parenting intervention to prevent affective disorders in high-risk adolescents: the PIPA trial protocol
- Author
-
Connor, C., Yap, M. B. H., Warwick, J., Birchwood, M., De Valliere, N., Madan, J., Melvin, G. A., Padfeld, E., Patterson, P., Petrou, S., Raynes, K., Stewart-Brown, S., and Thompson, A.
- Published
- 2022
- Full Text
- View/download PDF
4. An online parenting intervention to prevent affective disorders in high-risk adolescents: the PIPA trial protocol
- Author
-
Connor, C., MBH, Yap, Warwick, J., Birchwood, M., De Valliere, N, Madan, J., Melvin, G. A., Padfield, E., Patterson, P., Petrou, S., Raynes, K., Stewart-Brown, S., and Thompson, A.
- Published
- 2022
- Full Text
- View/download PDF
5. An iPSC line (FINi003-A) from a male with late-onset developmental and epileptic encephalopathy caused by a heterozygous p.E1211K variant in the SCN2A gene encoding the voltage-gated sodium channel Nav1.2
- Author
-
Ovchinnikov, DA, Jong, S, Cuddy, C, Dalby, K, Devinsky, O, Mullen, S, Maljevic, S, Petrou, S, Ovchinnikov, DA, Jong, S, Cuddy, C, Dalby, K, Devinsky, O, Mullen, S, Maljevic, S, and Petrou, S
- Abstract
Many developmental and epileptic encephalopathies (DEEs) result from variants in cation channel genes. Using mRNA transfection, we generated and characterised an induced pluripotent stem cell (iPSC) line from the fibroblasts of a male late-onset DEE patient carrying a heterozygous missense variant (E1211K) in Nav1.2(SCN2A) protein. The iPSC line displays features characteristic of the human iPSCs, colony morphology and expression of pluripotency-associated marker genes, ability to produce derivatives of all three embryonic germ layers, and normal karyotype without SNP array-detectable abnormalities. We anticipate that this iPSC line will aid in the modelling and development of precision therapies for this debilitating condition.
- Published
- 2024
6. PCR270 Development of a Quality Appraisal Tool for Systematic Literature Reviews of Studies Eliciting Health State Utility Values (HSUVs): A Delphi Consensus Approach
- Author
-
Muchadeyi, M., primary, Hernandez-Villafuerte, K., additional, Di Tanna, G.L., additional, Eckford, R., additional, Feng, Y., additional, Meregaglia, M., additional, Peasgood, T., additional, Petrou, S., additional, Ubels, J., additional, and Schlander, M., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Protocol for the Weight-bearing in Ankle Fractures (WAX) trial: a multicentre prospective non-inferiority trial of early versus delayed weight-bearing after operatively managed ankle fracture
- Author
-
Bretherton, C. P., Claireaux, H. A., Achten, J., Athwal, A., Dutton, S. J., Peckham, N., Petrou, S., Kearney, R. S., Appelbe, D., and Griffin, X. L.
- Published
- 2021
- Full Text
- View/download PDF
8. Generation of an iPSC line (FINi001-A) from a female developmental and epileptic encephalopathy patient due to a heterozygous gain-of-function p.R1882Q variant in the voltage-gated sodium channel Nav1.2 protein encoded by the SCN2A gene
- Author
-
Ovchinnikov, D.A., primary, Jong, S., additional, Cuddy, C., additional, Scheffer, I.E., additional, Maljevic, S., additional, and Petrou, S., additional
- Published
- 2023
- Full Text
- View/download PDF
9. TEMPERATURE-SENSITIVITY OF GABAA RECEPTOR TRAFFICKING IN A MOUSE MODEL OF FEBRILE SEIZURES
- Author
-
Hill, Elisa L, Mulligan, R, Richards, K, Baram, Tallie Z, Tan, H, Davies, P, and Petrou, S
- Subjects
Clinical Sciences ,Neurosciences ,Neurology & Neurosurgery - Published
- 2008
10. Discovering the pharmacodynamics of conolidine and cannabidiol using a cultured neuronal network based workflow
- Author
-
Mendis, G. D. C., Berecki, G., Morrisroe, E., Pachernegg, S., Li, M., Varney, M., Osborne, P. B., Reid, C. A., Halgamuge, S., and Petrou, S.
- Published
- 2019
- Full Text
- View/download PDF
11. Improving the understanding and management of back pain in older adults: the BOOST research programme including RCT and OPAL cohort
- Author
-
Williamson, E, Sanchez-Santos, M, Marian, I, Maredza, M, Srikesavan, C, Garrett, A, Morris, A, Boniface, G, Dutton, S, Griffiths, F, Collins, G, Petrou, S, Bruce, J, Fairbank, J, Hansen, Z, Barker, K, Hutchinson, C, Mallen, C, Ward, L, Gagen, R, Fitch, J, French, DP, and Lamb, SE
- Published
- 2023
12. Carbogen-Induced Respiratory Acidosis Blocks Experimental Seizures by a Direct and Specific Inhibition of NaV1.2 Channels in the Axon Initial Segment of Pyramidal Neurons
- Author
-
Hatch, RJ, Berecki, G, Jancovski, N, Li, M, Rollo, B, Jafar-Nejad, P, Rigo, F, Kaila, K, Reid, CA, Petrou, S, Hatch, RJ, Berecki, G, Jancovski, N, Li, M, Rollo, B, Jafar-Nejad, P, Rigo, F, Kaila, K, Reid, CA, and Petrou, S
- Abstract
Brain pH is a critical factor for determining neuronal activity, with alkalosis increasing and acidosis reducing excitability. Acid shifts in brain pH through the breathing of carbogen (5% CO2/95% O2) reduces seizure susceptibility in animal models and patients. The molecular mechanisms underlying this seizure protection remain to be fully elucidated. Here, we demonstrate that male and female mice exposed to carbogen are fully protected from thermogenic-triggered seizures. Whole-cell patch-clamp recordings revealed that acid shifts in extracellular pH (pHo) significantly reduce action potential firing in CA1 pyramidal neurons but did not alter firing in hippocampal inhibitory interneurons. In real-time dynamic clamp experiments, acidification reduced simulated action potential firing generated in hybrid model neurons expressing the excitatory neuron predominant NaV1.2 channel. Conversely, acidification had no effect on action potential firing in hybrid model neurons expressing the interneuron predominant NaV1.1 channel. Furthermore, knockdown of Scn2a mRNA in vivo using antisense oligonucleotides reduced the protective effects of carbogen on seizure susceptibility. Both carbogen-mediated seizure protection and the reduction in CA1 pyramidal neuron action potential firing by low pHo were maintained in an Asic1a knock-out mouse ruling out this acid-sensing channel as the underlying molecular target. These data indicate that the acid-mediated reduction in excitatory neuron firing is mediated, at least in part, through the inhibition of NaV1.2 channels, whereas inhibitory neuron firing is unaffected. This reduction in pyramidal neuron excitability is the likely basis of seizure suppression caused by carbogen-mediated acidification.SIGNIFICANCE STATEMENT Brain pH has long been known to modulate neuronal excitability. Here, we confirm that brain acidification reduces seizure susceptibility in a mouse model of thermogenic seizures. Extracellular acidification reduced excit
- Published
- 2023
13. Gestational age and hospital admission costs from birth to childhood: a population-based record linkage study in England
- Author
-
Hua, X, Petrou, S, Coathup, V, Carson, C, Kurinczuk, JJ, Quigley, MA, Boyle, E, Johnson, S, Macfarlane, A, Rivero-Arias, O, Hua, X, Petrou, S, Coathup, V, Carson, C, Kurinczuk, JJ, Quigley, MA, Boyle, E, Johnson, S, Macfarlane, A, and Rivero-Arias, O
- Abstract
OBJECTIVE: To examine the association between gestational age at birth and hospital admission costs from birth to 8 years of age. DESIGN: Population-based, record linkage, cohort study in England. SETTING: National Health Service (NHS) hospitals in England, UK. PARTICIPANTS: 1 018 136 live, singleton births in NHS hospitals in England between 1 January 2005 and 31 December 2006. MAIN OUTCOME MEASURES: Hospital admission costs from birth to age 8 years, estimated by gestational age at birth (<28, 28-29, 30-31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 and 42 weeks). RESULTS: Both birth admission and subsequent admission hospital costs decreased with increasing gestational age at birth. Differences in hospital admission costs between gestational age groups diminished with increasing age, particularly after the first 2 years following birth. Children born extremely preterm (<28 weeks) and very preterm (28-31 weeks) still had higher average hospital admission costs (£699 (95% CI £419 to £919) for <28 weeks; £434 (95% CI £305 to £563) for 28-31 weeks) during the eighth year of life compared with children born at 40 weeks (£109, 95% CI £104 to £114). Children born extremely preterm had the highest 8-year cumulative hospital admission costs per child (£80 559 (95% CI £79 238 to £82 019)), a large proportion of which was incurred during the first year after birth (£71 997 (95% CI £70 866 to £73 097)). CONCLUSIONS: The association between gestational age at birth and hospital admission costs persists into mid-childhood. The study results provide a useful costing resource for future economic evaluations focusing on preventive and treatment strategies for babies born preterm.
- Published
- 2023
14. Systematic Review of the Relative Social Value of Child and Adult Health.
- Author
-
Peasgood, T, Howell, M, Raghunandan, R, Salisbury, A, Sellars, M, Chen, G, Coast, J, Craig, JC, Devlin, NJ, Howard, K, Lancsar, E, Petrou, S, Ratcliffe, J, Viney, R, Wong, G, Norman, R, Donaldson, C, Quality Of Life in Kids: Key evidence to strengthen decisions in Australia (QUOKKA), Tools for Outcomes Research to measure, value Child Health (TORCH) project teams, Peasgood, T, Howell, M, Raghunandan, R, Salisbury, A, Sellars, M, Chen, G, Coast, J, Craig, JC, Devlin, NJ, Howard, K, Lancsar, E, Petrou, S, Ratcliffe, J, Viney, R, Wong, G, Norman, R, Donaldson, C, and Quality Of Life in Kids: Key evidence to strengthen decisions in Australia (QUOKKA), Tools for Outcomes Research to measure, value Child Health (TORCH) project teams
- Abstract
OBJECTIVES: We aimed to synthesise knowledge on the relative social value of child and adult health. METHODS: Quantitative and qualitative studies that evaluated the willingness of the public to prioritise treatments for children over adults were included. A search to September 2023 was undertaken. Completeness of reporting was assessed using a checklist derived from Johnston et al. Findings were tabulated by study type (matching/person trade-off, discrete choice experiment, willingness to pay, opinion survey or qualitative). Evidence in favour of children was considered in total, by length or quality of life, methodology and respondent characteristics. RESULTS: Eighty-eight studies were included; willingness to pay (n = 9), matching/person trade-off (n = 12), discrete choice experiments (n = 29), opinion surveys (n = 22) and qualitative (n = 16), with one study simultaneously included as an opinion survey. From 88 studies, 81 results could be ascertained. Across all studies irrespective of method or other characteristics, 42 findings supported prioritising children, while 12 provided evidence favouring adults in preference to children. The remainder supported equal prioritisation or found diverse or unclear views. Of those studies considering prioritisation within the under 18 years of age group, nine findings favoured older children over younger children (including for life saving interventions), six favoured younger children and five found diverse views. CONCLUSIONS: The balance of evidence suggests the general public favours prioritising children over adults, but this view was not found across all studies. There are research gaps in understanding the public's views on the value of health gains to very young children and the motivation behind the public's views on the value of child relative to adult health gains. CLINICAL TRIAL REGISTRATION: The review is registered at PROSPERO number: CRD42021244593. There were two amendments to the protocol: (1) some additiona
- Published
- 2023
15. Symptomatic SARS-CoV-2 episodes and health-related quality of life
- Author
-
Alacevich, C, Thalmann, I, Nicodemo, C, de Lusignan, S, and Petrou, S
- Subjects
Economics and Econometrics ,Health Policy ,General Medicine - Abstract
Background Understanding the physical and mental health needs of the population through evidence-based research is a priority for informing health policy. During the COVID-19 pandemic, population wellbeing dramatically dropped. The relationship between experiences of symptomatic illness episodes and health-related quality of life has been less documented. Objective This study analysed the association between symptomatic COVID-19 illness and health-related quality of life. Methods The analyses drew from a cross-sectional analysis of data from a national digital symptoms’ surveillance survey conducted in the UK in 2020. We identified illness episodes using symptoms and test results data and we analysed validated health-related quality of life outcomes including health utility scores (indexed on a 0–1 cardinal scale) and visual analogue scale (VAS) scores (0–100 scale) generated by the EuroQoL’s EQ-5D-5L measure. The econometric model controlled for respondents’ demographic and socioeconomic characteristics, comorbidities, social isolation measures, and regional and time fixed effects. Results The results showed that the experience of common SARS-CoV-2 symptoms was significantly associated with poorer health-related quality of life across all EQ-5D-5L dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression, a decrement in utility score of − 0.13 and a decrement in the EQ-VAS score of − 15. The findings were robust to sensitivity analyses and restrictive test results-based definitions. Conclusion This evidence-based study highlights the need for targeting of interventions and services towards those experiencing symptomatic episodes during future waves of the pandemic and helps to quantify the benefits of SARS-CoV-2 treatment in terms of health-related quality of life.
- Published
- 2023
16. Comparative evaluation of the health utilities index mark 3 and the short form 6D: evidence from an individual participant data meta-analysis of very preterm and very low birthweight adults
- Author
-
Bolbocean, C, Anderson, PJ, Bartmann, P, Cheong, JLY, Doyle, LW, Wolke, D, and Petrou, S
- Subjects
Public Health, Environmental and Occupational Health - Abstract
Background The most appropriate preference-based health-related quality of life (HRQoL) instruments for trials or research studies that ascertain the consequences of individuals born very preterm and/or low birthweight (VP/VLBW) are not known. Agreement between the HUI3 and SF-6D multi-attribute utility measures have not been previously investigated for VP/VLBW and normal birthweight or term-born controls. This study examined the agreement between the outputs of the HUI3 and SF-6D measures among adults born VP/VLBW and normal birthweight or term born controls. Methods We used two prospective cohorts of individuals born VP/VLBW and controls contributing to the ‘Research on European Children and Adults Born Preterm’ (RECAP) consortium which assessed HRQoL using two preference-based measures. The combined dataset of individual participant data (IPD) included 407 adult VP/VLBW survivors and 367 controls, ranging in age from 18 to 26 years. Bland–Altman plots, intra-class correlation coefficients, and generalized linear mixed models in a one-step approach were used to examine agreement between the measures. Results There was significant discordance between the HUI3 and SF-6D multi-attribute utility measures in the VP/VLBW sample, controls, and in the combined samples. Agreement between the HUI3 and SF-6D multi-attribute utility measures was weaker in controls compared with VP/VLBW individuals. Conclusions and relevance The HUI3 and SF-6D each provide unique information on different aspects of health status across the groups. The HUI3 better captures preterm-related changes to HRQoL in adulthood compared to SF-6D. Studies focused on measuring physical or cognitive aspects of health will likely benefit from using the HUI3 instead of the SF-6D, regardless of gestational age at birth and birthweight status.
- Published
- 2023
17. Pain with neuropathic characteristics after surgically treated lower limb fractures: cost analysis and pain medication use
- Author
-
Png, ME, Costa, M, Petrou, S, Achten, J, Knight, R, Bruce, J, and Keene, D
- Abstract
Introduction: Neuropathic pain is prevalent among people after lower limb fracture surgery, and is associated with lower health-related quality-of-life and greater disability. This study estimates the financial cost and pain medication use associated with neuropathic pain in this group. Methods: A secondary analysis using pain data collected over six postoperative months from participants randomised in the Wound Healing in Surgery for Trauma (WHiST) trial. Pain states were classified as painfree, chronic non-neuropathic pain (NNP) or chronic neuropathic pain (NP). Cost associated with each pain state from a UK National Health Service (NHS) and personal social services (PSS) perspective were estimated by multivariate models based on multiple imputed data. Pain medication usage was analysed by pain state. Results: A total of 934 participants who provided either three- or six-months pain data were included. Compared to participants with NP, those with NNP (adjusted mean difference -£730, p=0.38, 95%CI -2368 to 908) or were pain-free (adjusted mean difference -£716, p=0.53, 95%CI -2,929 to 1,497) had lower costs from the NHS and PSS perspective in the first three postoperative months. Over the first three postoperative months almost a third of participants with NP were prescribed opioids, 8% were prescribed NP medications. Similar trends were observed by six months postoperatively. Conclusion: This study found healthcare costs were higher amongst those with chronic NP compared to those who were pain-free or had chronic NNP. Opioids, rather than neuropathic pain medications, were commonly prescribed for NP over the first six postoperative months, contrary to clinical guidelines.
- Published
- 2023
18. Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation
- Author
-
Rivero-Arias, O, Png, ME, White, A, Yang, M, McNiven, A, Ratushnyak, S, Roberts, N, Shilton Osborne, J, and Petrou, S
- Published
- 2023
19. Psychometric performance of the Chichewa versions of the EQ-5D-Y-3L and EQ-5D-Y-5L among healthy and sick children and adolescents in Malawi
- Author
-
Ngwira, LG, Maheswaran, H, Verstraete, J, Petrou, S, Niessen, L, and Smith, SC
- Subjects
Health Information Management ,Health Informatics - Abstract
Objectives The EuroQol Group has developed an extended version of the EQ-5D-Y-3L with five response levels for each of its five dimensions (EQ-5D-Y-5L). The psychometric performance has been reported in several studies for the EQ-5D-Y-3L but not for the EQ-5D-Y-5L. This study aimed to psychometrically evaluate the EQ-5D-Y-3L and EQ-5D-Y-5L Chichewa (Malawi) versions. Methods The EQ-5D-Y-3L, EQ-5D-Y-5L and PedsQL™ 4.0 Chichewa versions were administered to children and adolescents aged 8–17 years in Blantyre, Malawi. Both of the EQ-5D-Y versions were evaluated for missing data, floor/ceiling effects, and validity (convergent, discriminant, known-group and empirical). Results A total of 289 participants (95 healthy, and 194 chronic and acute) self-completed the questionnaires. There was little problem with missing data (p > 0.05) with respect to gender and age, but not for school grade (p Conclusions Both versions of the EQ-5D-Y-3L and EQ-5D-Y-5L had issues with missing data in younger children. Convergent validity, discriminant validity with respect to gender and age, and known-group validity of either measures were also met for use among children and adolescents in this population, although with some limitations (discriminant validity by grade and empirical validity). The EQ-5D-Y-3L seems particularly suited for use in younger children (8–12 years) and the EQ-5D-Y-5L in adolescents (13–17 years). However, further psychometric testing is required for test re-test reliability and responsiveness that could not be carried out in this study due to COVID-19 restrictions.
- Published
- 2023
20. Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review
- Author
-
Bailey, C, Howell, M, Raghunandan, R, Salisbury, A, Chen, G, Coast, J, Craig, JC, Devlin, NJ, Huynh, E, Lancsar, E, Mulhern, BJ, Norman, R, Petrou, S, Ratcliffe, J, Street, DJ, Howard, K, Viney, R, Dalziel, K, Hiscock, H, Hayes, A, Wong, G, Donaldson, C, Carter, S, and The Quality of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA), Tools for Outcomes Research to Measure, Value Child Health (TORCH) Project Teams
- Subjects
Pharmacology ,Health Policy ,Public Health, Environmental and Occupational Health - Abstract
Background and Objectives Valuing children’s health states for use in economic evaluations is globally relevant and is of particular relevance in jurisdictions where a cost-utility analysis is the preferred form of analysis for decision making. Despite this, the challenges with valuing child health mean that there are many remaining questions for debate about the approach to elicitation of values. The aim of this paper was to identify and describe the methods used to value children’s health states and the specific issues that arise in the use of these methods. Methods We conducted a systematic search of electronic databases to identify studies published in English since 1990 that used preference elicitation methods to value child and adolescent (under 18 years of age) health states. Eligibility criteria comprised valuation studies concerning both child-specific patient-reported outcome measures and child health states defined in other ways, and methodological studies of valuation approaches that may or may not have yielded a value set algorithm. Results A total of 77 eligible studies were identified from which data on country setting, aims, condition (general population or clinically specific), sample size, age of respondents, the perspective that participants were asked to adopt, source of values (respondents who completed the preference elicitation tasks) and methods questions asked were extracted. Extracted data were classified and evaluated using narrative synthesis methods. The studies were classified into three groups: (1) studies comparing elicitation methods (n = 30); (2) studies comparing perspectives (n = 23); and (3) studies where no comparisons were presented (n = 26); selected studies could fall into more than one group. Overall, the studies varied considerably both in methods used and in reporting. The preference elicitation tasks included time trade-off, standard gamble, visual analogue scaling, rating/ranking, discrete choice experiments, best-worst scaling and willingness to pay elicited through a contingent valuation. Perspectives included adults’ considering the health states from their own perspective, adults taking the perspective of a child (own, other, hypothetical) and a child/adolescent taking their own or the perspective of another child. There was some evidence that children gave lower values for comparable health states than did adults that adopted their own perspective or adult/parents that adopted the perspective of children. Conclusions Differences in reporting limited the conclusions that can be formed about which methods are most suitable for eliciting preferences for children’s health and the influence of differing perspectives and values. Difficulties encountered in drawing conclusions from the data (such as lack of consensus and poor reporting making it difficult for users to choose and interpret available values) suggest that reporting guidelines are required to improve the consistency and quality of reporting of studies that value children’s health using preference-based techniques.
- Published
- 2022
21. EE596 Comparative Evaluation of the Health Utilities Index Mark 3 and the Short Form-6D: Evidence From an Individual Participant Data Meta-Analysis of Very Preterm and Very Low Birthweight Adults
- Author
-
Bolbocean, C, primary and Petrou, S, additional
- Published
- 2022
- Full Text
- View/download PDF
22. No exponential rise in revision knee replacement surgery over the past 15 years: an analysis from the National Joint Registry
- Author
-
Sabah, S.A., primary, Knight, R., additional, Alvand, A., additional, Murray, D.W., additional, Petrou, S., additional, Beard, D.J., additional, and Price, A.J., additional
- Published
- 2022
- Full Text
- View/download PDF
23. MSR68 Development of a Checklist for Studies Reporting the Elicitation of Stated Preferences Values for Child Health Related Quality of Life
- Author
-
Bailey, C, primary, Howell, M, additional, Raghunandan, R, additional, Dalziel, K, additional, Howard, K, additional, Mulhern, B, additional, Petrou, S, additional, Rowen, D, additional, Salisbury, A, additional, Viney, R, additional, Lancsar, E, additional, and Devlin, N, additional
- Published
- 2022
- Full Text
- View/download PDF
24. PCR190 Health-Related Quality of Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis
- Author
-
Bolbocean, C, primary and Petrou, S, additional
- Published
- 2022
- Full Text
- View/download PDF
25. WAO consensus on definition of food allergy severity (DEFASE)
- Author
-
Arasi, S, Nurmatov, U, Dunn-Galvin, A, Roberts, G, Turner, PJ, Shinder, SB, Gupta, R, Eigenmann, P, Nowak-Wegrzyn, A, Ansotegui, IJ, Rivas, MF, Petrou, S, Tanno, LK, Vazquez-Ortiz, M, Vickery, B, Wong, G, Alvaro-Lozano, M, Asaria, M, Begin, P, Bozzola, M, Boyle, R, Brough, H, Cardona, V, Chinthrajah, RS, Cianferoni, A, Deschildre, A, Fleischer, D, Gazzani, F, Gerdts, J, Giannetti, M, Greenhawt, M, Guzmán, MA, Hossny, E, Kauppi, P, Jones, C, Lucidi, F, Monge Ortega, OP, Munblit, D, Muraro, A, Pajno, G, Podestà, M, Rodriguez del Rio, P, Said, M, Santos, A, Shaker, M, Szajewska, H, Venter, C, Warren, C, Winders, T, Ebisawa, M, and Fiocchi, A
- Subjects
Pulmonary and Respiratory Medicine ,consensus ,definition ,food allergy ,severity ,e-delphi study ,RA0421 Public health. Hygiene. Preventive Medicine ,Immunology ,Immunology and Allergy ,R Medicine (General) - Abstract
Background: While several scoring systems for the severity of anaphylactic reactions have been developed, there is a lack of consensus on definition and categorisation of severity of food allergy disease as a whole. Aim: To develop an international consensus on the severity of food allergy (DEfinition of Food Allergy Severity, DEFASE) scoring system, to be used globally. Methods: Phase 1: We conducted a mixed-method systematic review (SR) of 11 databases for published and unpublished literature on severity of food allergy management and set up a panel of international experts. Phase 2: Based on our findings in Phase 1, we drafted statements for a two-round modified electronic Delphi (e-Delphi) survey. A purposefully selected multidisciplinary international expert panel on food allergy (n = 60) was identified and sent a structured questionnaire, including a set of statements on different domains of food allergy severity related to symptoms, health-related quality of life, and economic impact. Participants were asked to score their agreement on each statement on a 5-point Likert scale ranging from “strongly agree” to “strongly disagree”. Median scores and percentage agreements were calculated. Consensus was defined a priori as being achieved if 70% or more of panel members rated a statement as “strongly agree” to “agree” after the second round. Based on feedback, 2 additional online voting rounds were conducted. Results: We received responses from 92% of Delphi panel members in round 1 and 85% in round 2. Consensus was achieved on the overall score and in all of the 5 specific key domains as essential components of the DEFASE score. Conclusions: The DEFASE score is the first comprehensive grading of food allergy severity that considers not only the severity of a single reaction, but the whole disease spectrum. An international consensus has been achieved regarding a scoring system for food allergy disease. It offers an evaluation grid, which may help to rate the severity of food allergy. Phase 3 will involve validating the scoring system in research settings, and implementing it in clinical practice.
- Published
- 2023
26. Induction of labour for predicted macrosomia: study protocol for the 'Big Baby' randomised controlled trial
- Author
-
Ewington, LJ, Gardosi, J, Lall, R, Underwood, M, Fisher, JD, Wood, S, Griffin, R, Harris, K, Bick, D, Booth, K, Brown, J, Butler, E, Fowler, K, Williams, M, Deshpande, S, Gornall, A, Dewdney, J, Hillyer, K, Gates, S, Jones, C, Mistry, H, Petrou, S, Slowther, A-M, Willis, A, and Quenby, S
- Subjects
Cesarean Section ,Infant, Newborn ,Infant ,Pilot Projects ,General Medicine ,Fetal Macrosomia ,Cohort Studies ,Pregnancy ,Humans ,Birth Weight ,Multicenter Studies as Topic ,Female ,Prospective Studies ,Labor, Induced ,Shoulder Dystocia ,Randomized Controlled Trials as Topic - Abstract
IntroductionLarge-for-gestational age (LGA) fetuses have an increased risk of shoulder dystocia. This can lead to adverse neonatal outcomes and death. Early induction of labour in women with a fetus suspected to be macrosomic may mitigate the risk of shoulder dystocia. The Big Baby Trial aims to find if induction of labour at 38+0–38+4weeks’ gestation, in pregnancies with suspected LGA fetuses, reduces the incidence of shoulder dystocia.Methods and analysisThe Big Baby Trial is a multicentre, prospective, individually randomised controlled trial of induction of labour at 38+0to 38+4weeks’ gestation vs standard care as per each hospital trust (median gestation of delivery 39+4) among women whose fetuses have an estimated fetal weight >90th customised centile according to ultrasound scan at 35+0to 38+0weeks’ gestation. There is a parallel cohort study for women who decline randomisation because they opt for induction, expectant management or caesarean section. Up to 4000 women will be recruited and randomised to induction of labour or to standard care. The primary outcome is the incidence of shoulder dystocia; assessed by an independent expert group, blind to treatment allocation, from delivery records. Secondary outcomes include birth trauma, fractures, haemorrhage, caesarean section rate and length of inpatient stay. The main trial is ongoing, following an internal pilot study. A qualitative reporting, health economic evaluation and parallel process evaluation are included.Ethics and disseminationThe study received a favourable opinion from the South West—Cornwall and Plymouth Health Research Authority on 23/03/2018 (IRAS project ID 229163). Study results will be reported in the National Institute for Health Research journal library and published in an open access peer-reviewed journal. We will plan dissemination events for key stakeholders.Trial registration numberISRCTN18229892.
- Published
- 2022
27. Derivation of a UK preference-based value set for the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) to allow estimation of Mental Well-being Adjusted Life Years (MWALYs)
- Author
-
Yiu, HHE, Buckell, J, Petrou, S, Stewart-Brown, S, and Madan, J
- Subjects
Health (social science) ,History and Philosophy of Science - Abstract
Background The Mental Well-being Adjusted Life Year (MWALY) is an alternative outcome measure to the quality-adjusted life year (QALY) in economic evaluations of interventions aimed at improving mental well-being. However, there is a lack of preference-based mental well-being instruments for capturing population mental well-being preferences. Objectives To derive a UK preference-based value set for the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS). Methods 225 participants that were interviewed between December 2020 and August 2021 completed 10 composite time trade-off (C-TTO) and 10 discrete choice experiment (DCE) interviewer-administered exercises. Heteroskedastic Tobit and conditional logit models were used to model C-TTO and DCE responses respectively. The DCE utility values were rescaled to a C-TTO comparable scale through anchoring and mapping. An inverse variance weighting hybrid model (IVWHM) was used to derive weighted-average coefficients from the modelled C-TTO and DCE coefficients. Model performance was assessed using statistical diagnostics. Results The valuation responses confirmed the feasibility and face validity of the C-TTO and DCE techniques. Apart from the main effects models, statistically significant associations were estimated between the predicted C-TTO value and participants’ SWEMWBS scores, gender, ethnicities, education levels, and the interaction terms between age and useful feeling. The IVWHM was the most optimal model with the fewest logically inconsistent coefficients and the lowest pooled standard errors. The utility values generated by the rescaled DCE models and the IVWHM were generally higher than those of the C-TTO model. The predictive ability of the two DCE rescaling methods was similar according to the mean absolute deviation and root mean square deviation statistics. Conclusions This study has produced the first preference-based value set for a measure of mental well-being. The IVWHM provided a desirable blend of both C-TTO and DCE models. The value set derived by this hybrid approach can be used for cost-utility analyses of mental well-being interventions.
- Published
- 2023
28. Health-related quality of life of children born very preterm : a multinational European cohort study
- Author
-
Kim, Sung Wook, Andronis, Lazaros, Seppänen, Anna-Veera, Aubert, Adrien M., Barros, Henrique, Draper, Elizabeth S., Sentenac, Mariane, Zeitlin, Jennifer, Petrou, Stavros, Lebeer, Jo, Van Reempts, Patrick, Bruneel, E., Cloet, E., Oostra, A., Ortibus, E., Sarrechia, Iemke, Boerch, K., Pedersen, P., Toome, L., Varendi, H., Männamaa, M., Ancel, P.Y., Burguet, A., Jarreau, P.H., Pierrat, V., Truffert, P., Maier, R.F., Zemlin, M., Misselwitz, B., Wohlers, L., Cuttini, M., Croci, I., Carnielli, V., Ancora, G., Faldella, G., Ferrari, F., van Heijst, A., Koopman-Esseboom, C., Gadzinowski, J., Mazela, J., Montgomery, A., Pikuła, T., Barros, H., Costa, R., Rodrigues, C., Aden, U., Draper, E.S., Fenton, A., Johnson, S.J., Mader, S., Thiele, N., Pfeil, J.M., Petrou, S., Kim, S.W., Andronis, L., Zeitlin, J., Aubert, A.M., Bonnet, C., El Rafei, R., Seppänen, A.V., and SHIPS Research Group
- Subjects
RJ ,Public Health, Environmental and Occupational Health ,Human medicine ,RG - Abstract
Purpose This study aims to (1) describe the health-related quality of life (HRQoL) outcomes experienced by children born very preterm (28–31 weeks’ gestation) and extremely preterm ( Methods This investigation was based on data for 3687 children born at ™ GCS scores. A mediation analysis that applied generalised structural equation modelling explored the association between potential mediators and PedsQL™ GCS scores. Results The multi-level OLS regression (fully adjusted model) revealed that birth at ™ GCS score of 0.35, 3.71 and 5.87, respectively. The mediation analysis revealed that the indirect effects of BPD and severe non-respiratory morbidity on the total PedsQL™ GCS score translated into decrements of 1.73 and 17.56, respectively, at Conclusion The findings suggest that HRQoL is particularly impaired by extremely preterm birth and the concomitant complications of preterm birth such as BPD and severe non-respiratory morbidity.
- Published
- 2022
29. Cost-utility analysis of cemented hemiarthroplasty versus hydroxyapatite-coated uncemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures: WHiTE5 trial
- Author
-
Png, ME, Petrou, S, Fernandez, M, Achten, J, Parsons, N, McGibbon, A, Gould, J, Griffin, X, and Costa, M
- Abstract
Aims: The aim of this study was to compare the cost-effectiveness of cemented hemiarthroplasty (HA) versus hydroxyapatite-coated uncemented HA for the treatment of displaced intracapsular hip fractures in older adults. Methods: A within-trial economic evaluation was conducted based on data collected from the World Hip Trauma Evaluation 5 (WHiTE 5) multicentre randomized controlled trial in the UK. Resource use was measured over 12 months post-randomization using trial case report forms and participant-completed questionnaires. Cost-effectiveness was reported in terms of incremental cost per quality-adjusted life year (QALY) gained from the NHS and personal social service perspective. Methodological uncertainty was addressed using sensitivity analysis, while decision uncertainty was represented graphically using confidence ellipses and cost-effectiveness acceptability curves. Results: The base-case analysis showed that cemented implants were cost-saving (mean cost difference -£961 (95% confidence interval (CI) -£2,292 to £370)) and increased QALYs (mean QALY difference 0.010 (95% CI 0.002 to 0.017)) when compared to uncemented implants. The probability of the cemented implant being cost-effective approximated between 95% and 97% at alternative cost-effectiveness thresholds held by decision-makers, and its net monetary benefit was positive. The findings remained robust against all the pre-planned sensitivity analyses. Conclusion: This study shows that cemented HA is cost-effective compared with hydroxyapatite-coated uncemented HA in older adults with displaced intracapsular hip fractures.
- Published
- 2022
30. Cross-Cultural Adaptation of the Beta EQ-5D-Y-5L Into Chichewa (Malawi)
- Author
-
Ngwira, Lucky-Gift, Jelsma, J, Maheswaran, H, Kapakasa, F, Petrou, S, Niessen, Louis, and Smith, S
- Subjects
wa_395 ,wa_100 ,wa_540 - Abstract
Objectives\ud The EuroQol Group is developing a new EQ-5D-Y-5L version with five severity levels for each of the five dimensions. The five severity levels describe different health severity and there is a potential for severity level inversion. This paper aims to report the process of cross-cultural\ud adaptation of the beta EQ-5D-Y-5L into Chichewa (Malawi) using the card ranking exercise which has been added to the EQ-5D-Y-5L translation protocol.\ud Methods\ud To assess correct hierarchical ordering of severity levels, the adaptation followed the EQ-5D-Y- 5L translation protocol. Cognitive interviews were undertaken to establish conceptual equivalence. Thereafter, four iterations of ranking exercises were conducted, leading to amendments of the translated Chichewa version to arrive at a final version.\ud Results\ud The iterations were assessed by 18 participants aged 8-14 years. Health proved to be a difficult concept to translate as was ‘discomfort’. Cognitive interviews identified further conceptual issues, particularly with the ‘looking after myself’ dimension. Considerations about lack of soap or water indicated that some children did not fully comprehend this dimension as being about the ability to wash and dress themselves. The iterative card ranking exercise detected severity level inversion\ud between ‘a little bit’ and ‘some’, and between ‘a lot’ and ‘extreme’ and alternative Chichewa words/phrases were then tested. Ultimately, intended hierarchical severity ranking was achieved and an acceptable Chichewa version produced.\ud Conclusions\ud Conceptual and linguistic equivalence to the English EQ-5D-Y-5L was established for the Chichewa EQ-5D-Y-5L version. The card ranking exercise was instrumental in correcting severity level inversion and supporting the comprehensible translation.\ud Key words: EQ-5D-Y-5L, EQ-5D-Y, childhood, ‘health-related quality of life, HRQoL, translation, adaptation, ranking exercise, sub-Saharan Africa
- Published
- 2022
31. Exercise to prevent shoulder problems after breast cancer surgery : the PROSPER RCT
- Author
-
Bruce, J, Mazuquin, B, Mistry, P, Rees, S, Canaway, A, Hossain, A, Williamson, E, Padfield, EJ, Lall, R, Richmond, H, Chowdhury, L, Lait, C, Petrou, S, Booth, K, Lamb, SE, Vidya, R, Thompson, AM, Bruce, J, Mazuquin, B, Mistry, P, Rees, S, Canaway, A, Hossain, A, Williamson, E, Padfield, EJ, Lall, R, Richmond, H, Chowdhury, L, Lait, C, Petrou, S, Booth, K, Lamb, SE, Vidya, R, and Thompson, AM
- Abstract
BACKGROUND: Upper limb problems are common after breast cancer treatment. OBJECTIVES: To investigate the clinical effectiveness and cost-effectiveness of a structured exercise programme compared with usual care on upper limb function, health-related outcomes and costs in women undergoing breast cancer surgery. DESIGN: This was a two-arm, pragmatic, randomised controlled trial with embedded qualitative research, process evaluation and parallel economic analysis; the unit of randomisation was the individual (allocated ratio 1 : 1). SETTING: Breast cancer centres, secondary care. PARTICIPANTS: Women aged ≥ 18 years who had been diagnosed with breast cancer and were at higher risk of developing shoulder problems. Women were screened to identify their risk status. INTERVENTIONS: All participants received usual-care information leaflets. Those randomised to exercise were referred to physiotherapy for an early, structured exercise programme (three to six face-to-face appointments that included strengthening, physical activity and behavioural change strategies). MAIN OUTCOME MEASURES: The primary outcome was upper limb function at 12 months as assessed using the Disabilities of Arm, Hand and Shoulder questionnaire. Secondary outcomes were function (Disabilities of Arm, Hand and Shoulder questionnaire subscales), pain, complications (e.g. wound-related complications, lymphoedema), health-related quality of life (e.g. EuroQol-5 Dimensions, five-level version; Short Form questionnaire-12 items), physical activity and health service resource use. The economic evaluation was expressed in terms of incremental cost per quality-adjusted life-year and incremental net monetary benefit gained from an NHS and Personal Social Services perspective. Participants and physiotherapists were not blinded to group assignment, but data collectors were blinded. RESULTS: Between 2016 and 2017, we randomised 392 participants from 17 breast cancer centres across England: 196 (50%) to the usual-care
- Published
- 2022
32. Association of ultra-rare coding variants with genetic generalized epilepsy: A case–control whole exome sequencing study
- Author
-
Koko, M, Motelow, JE, Stanley, KE, Bobbili, DR, Dhindsa, RS, May, P, Alldredge, BK, Allen, AS, Altmüller, J, Amrom, D, Andermann, E, Auce, P, Avbersek, A, Baulac, S, Bautista, JF, Becker, F, Bellows, Susannah, Berghuis, B, Berkovic, SF, Bluvstein, J, Boro, A, Bridgers, J, Burgess, R, Caglayan, H, Cascino, GD, Cavalleri, GL, Chung, SK, Cieuta-Walti, C, Cloutier, V, Consalvo, D, Cossette, P, Crumrine, P, Delanty, N, Depondt, C, Desbiens, R, Devinsky, O, Dlugos, D, Epstein, MP, Everett, K, Fiol, M, Fountain, NB, Francis, B, French, J, Freyer, C, Friedman, D, Gambardella, A, Geller, EB, Girard, S, Glauser, T, Glynn, S, Goldstein, DB, Gravel, M, Haas, K, Haut, SR, Heinzen, EL, Helbig, I, Hildebrand, MS, Johnson, MR, Jorgensen, A, Joshi, S, Kanner, A, Kirsch, HE, Klein, KM, Knowlton, RC, Koeleman, BPC, Kossoff, EH, Krause, R, Krenn, M, Kunz, WS, Kuzniecky, R, Langley, SR, LeGuern, E, Lehesjoki, AE, Lerche, H, Leu, C, Lortie, A, Lowenstein, DH, Marson, AG, Mebane, C, Mefford, HC, Meloche, C, Moreau, C, Motika, PV, Muhle, H, Møller, RS, Nabbout, R, Nguyen, DK, Nikanorova, M, Novotny, EJ, Nürnberg, P, Ottman, R, O’Brien, TJ, Paolicchi, JM, Parent, JM, Park, K, Peter, S, Petrou, S, Petrovski, S, Pickrell, WO, Poduri, A, Koko, M, Motelow, JE, Stanley, KE, Bobbili, DR, Dhindsa, RS, May, P, Alldredge, BK, Allen, AS, Altmüller, J, Amrom, D, Andermann, E, Auce, P, Avbersek, A, Baulac, S, Bautista, JF, Becker, F, Bellows, Susannah, Berghuis, B, Berkovic, SF, Bluvstein, J, Boro, A, Bridgers, J, Burgess, R, Caglayan, H, Cascino, GD, Cavalleri, GL, Chung, SK, Cieuta-Walti, C, Cloutier, V, Consalvo, D, Cossette, P, Crumrine, P, Delanty, N, Depondt, C, Desbiens, R, Devinsky, O, Dlugos, D, Epstein, MP, Everett, K, Fiol, M, Fountain, NB, Francis, B, French, J, Freyer, C, Friedman, D, Gambardella, A, Geller, EB, Girard, S, Glauser, T, Glynn, S, Goldstein, DB, Gravel, M, Haas, K, Haut, SR, Heinzen, EL, Helbig, I, Hildebrand, MS, Johnson, MR, Jorgensen, A, Joshi, S, Kanner, A, Kirsch, HE, Klein, KM, Knowlton, RC, Koeleman, BPC, Kossoff, EH, Krause, R, Krenn, M, Kunz, WS, Kuzniecky, R, Langley, SR, LeGuern, E, Lehesjoki, AE, Lerche, H, Leu, C, Lortie, A, Lowenstein, DH, Marson, AG, Mebane, C, Mefford, HC, Meloche, C, Moreau, C, Motika, PV, Muhle, H, Møller, RS, Nabbout, R, Nguyen, DK, Nikanorova, M, Novotny, EJ, Nürnberg, P, Ottman, R, O’Brien, TJ, Paolicchi, JM, Parent, JM, Park, K, Peter, S, Petrou, S, Petrovski, S, Pickrell, WO, and Poduri, A
- Published
- 2022
33. Sodium channel expression and transcript variation in the developing brain of human, Rhesus monkey, and mouse
- Author
-
Heighway, J, Sedo, A, Garg, A, Eldershaw, L, Perreau, V, Berecki, G, Reid, CA, Petrou, S, Maljevic, S, Heighway, J, Sedo, A, Garg, A, Eldershaw, L, Perreau, V, Berecki, G, Reid, CA, Petrou, S, and Maljevic, S
- Abstract
Genetic variation in voltage-gated sodium (NaV) channels is a significant contributor to neurodevelopmental disorders. NaV channel alpha subunits are encoded by the SCNxA family and four are predominately expressed in the brain: SCN1A, SCN2A, SCN3A, and SCN8A. Gene expression is developmentally regulated, and they are known to express functionally distinct transcript variants. Precision therapies targeting these genes and their transcript variants are currently in preclinical development, yet the developmental expression of these transcripts in the human brain is yet to be fully understood. Additionally, the functional consequences of some mutations differ depending on the studied channel isoform, suggesting differential transcript variant expression can affect disease prognoses. We characterise the expression of the four SCNxAs and their transcript variants in human, Rhesus monkey and mouse brain using publicly available RNA-sequencing data and analysis tools, demonstrating that this approach can be used to answer important biological questions of gene and transcript developmental regulation. We find that gene expression and transcript variant regulation are conserved across species at similar developmental stages and determine the developmental milestones for transcript variant expression. Our study provides a guide to researchers testing therapies and clinicians advising prognoses based on the expression of channel isoforms.
- Published
- 2022
34. Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
- Author
-
Kwon, J, Freijser, L, Huynh, E, Howell, M, Chen, G, Khan, K, Daher, S, Roberts, N, Harrison, C, Smith, S, Devlin, N, Howard, K, Lanscar, E, Bailey, C, Craig, J, Dalziel, K, Hayes, A, Mulhern, B, Wong, G, Ratcliffe, J, Petrou, S, Kwon, J, Freijser, L, Huynh, E, Howell, M, Chen, G, Khan, K, Daher, S, Roberts, N, Harrison, C, Smith, S, Devlin, N, Howard, K, Lanscar, E, Bailey, C, Craig, J, Dalziel, K, Hayes, A, Mulhern, B, Wong, G, Ratcliffe, J, and Petrou, S
- Abstract
BACKGROUND AND AIMS: Patient-reported outcome measures (PROMs) for children (aged ≤ 18 years) present methodological challenges. PROMs can be categorised by their diverse underlying conceptual bases, including functional, disability and health (FDH) status; quality of life (QoL); and health-related quality of life (HRQoL). Some PROMs are designed to be accompanied by preference weights. PROMs should account for childhood developmental differences by incorporating age-appropriate health/QoL domains, guidance on respondent type(s) and design. This systematic review aims to identify generic multidimensional childhood PROMs and synthesise their characteristics by conceptual basis, target age, measurement considerations, and the preference-based value sets that accompany them. METHODS: The study protocol was registered in the Prospective Register of Systematic Reviews (CRD42021230833), and reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We conducted systematic database searches for generic multidimensional childhood PROMs covering the period 2012-2020, which we combined with published PROMs identified by an earlier systematic review that covered the period 1992-2011. A second systematic database search identified preference-based value sets for generic multidimensional PROMs. The PROMs were categorised by conceptual basis (FDH status, QoL and HRQoL) and by target age (namely infants and pre-schoolers aged < 5 years, pre-adolescents aged 5-11, adolescents aged 12-18 and multi-age group coverage). Descriptive statistics assessed how PROM characteristics (domain coverage, respondent type and design) varied by conceptual basis and age categories. Involvement of children in PROM development and testing was assessed to understand content validity. Characteristics of value sets available for the childhood generic multidimensional PROMs were identified and compared. RESULTS: We identified 89 PROMs, including 110 versions
- Published
- 2022
35. Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures (Jan, 10.1007/s40273-021-01128-0, 2022)
- Author
-
Kwon, J, Freijser, L, Huynh, E, Howell, M, Chen, G, Khan, K, Daher, S, Roberts, N, Harrison, C, Smith, S, Devlin, N, Howard, K, Lancsar, E, Bailey, C, Craig, J, Dalziel, K, Hayes, A, Mulhern, B, Wong, G, Ratcliffe, J, Petrou, S, Kwon, J, Freijser, L, Huynh, E, Howell, M, Chen, G, Khan, K, Daher, S, Roberts, N, Harrison, C, Smith, S, Devlin, N, Howard, K, Lancsar, E, Bailey, C, Craig, J, Dalziel, K, Hayes, A, Mulhern, B, Wong, G, Ratcliffe, J, and Petrou, S
- Published
- 2022
36. The health and educational costs of preterm birth to 18 years of age in Australia.
- Author
-
Newnham, JP, Schilling, C, Petrou, S, Morris, JM, Wallace, EM, Brown, K, Edwards, L, Skubisz, MM, White, SW, Rynne, B, Arrese, CA, Doherty, DA, Newnham, JP, Schilling, C, Petrou, S, Morris, JM, Wallace, EM, Brown, K, Edwards, L, Skubisz, MM, White, SW, Rynne, B, Arrese, CA, and Doherty, DA
- Abstract
BACKGROUND: Preterm birth is the greatest cause of death up to five years of age and an important contributor to lifelong disability. There is increasing evidence that a meaningful proportion of early births may be prevented, but widespread introduction of effective preventive strategies will require financial support. AIMS: This study estimated the economic cost to the Australian government of preterm birth, up to 18 years of age. MATERIALS AND METHODS: A decision-analytic model was developed to estimate the costs of preterm birth in Australia for a hypothetical cohort of 314 814 children, the number of live births in 2016. Costs to Australia's eight jurisdictions included medical expenditures and additional costs to educational services. RESULTS: The total cost of preterm birth to the Australian government associated with the annual cohort was estimated at $1.413 billion (95% CI 1047-1781). Two-thirds of the costs were borne by healthcare services during the newborn period and one-quarter of the costs by educational services providing special assistance. For each child, the costs were highest for those born at the earliest survivable gestational age, but the larger numbers of children born at later gestational ages contributed heavily to the overall economic burden. CONCLUSION: Preterm birth leaves many people with lifelong disabilities and generates a significant economic burden to society. The costs extend beyond those to the healthcare system and include additional educational needs. Assessments of economic costs should inform economic evaluations of interventions aimed at the prevention or treatment of preterm birth.
- Published
- 2022
37. Loss-of-function variants in the KCNQ5 gene are implicated in genetic generalized epilepsies
- Author
-
Krueger, J, Schubert, J, Kegele, J, Labalme, A, Mao, M, Heighway, J, Seebohm, G, Yan, P, Koko, M, Aslan-Kara, K, Caglayan, H, Steinhoff, BJ, Weber, YG, Keo-Kosal, P, Berkovic, SF, Hildebrand, MS, Petrou, S, Krause, R, May, P, Lesca, G, Maljevic, S, Lerche, H, Krueger, J, Schubert, J, Kegele, J, Labalme, A, Mao, M, Heighway, J, Seebohm, G, Yan, P, Koko, M, Aslan-Kara, K, Caglayan, H, Steinhoff, BJ, Weber, YG, Keo-Kosal, P, Berkovic, SF, Hildebrand, MS, Petrou, S, Krause, R, May, P, Lesca, G, Maljevic, S, and Lerche, H
- Abstract
BACKGROUND: De novo missense variants in KCNQ5, encoding the voltage-gated K+ channel KV7.5, have been described to cause developmental and epileptic encephalopathy (DEE) or intellectual disability (ID). We set out to identify disease-related KCNQ5 variants in genetic generalized epilepsy (GGE) and their underlying mechanisms. METHODS: 1292 families with GGE were studied by next-generation sequencing. Whole-cell patch-clamp recordings, biotinylation and phospholipid overlay assays were performed in mammalian cells combined with homology modelling. FINDINGS: We identified three deleterious heterozygous missense variants, one truncation and one splice site alteration in five independent families with GGE with predominant absence seizures; two variants were also associated with mild to moderate ID. All missense variants displayed a strongly decreased current density indicating a loss-of-function (LOF). When mutant channels were co-expressed with wild-type (WT) KV7.5 or KV7.5 and KV7.3 channels, three variants also revealed a significant dominant-negative effect on WT channels. Other gating parameters were unchanged. Biotinylation assays indicated a normal surface expression of the variants. The R359C variant altered PI(4,5)P2-interaction. INTERPRETATION: Our study identified deleterious KCNQ5 variants in GGE, partially combined with mild to moderate ID. The disease mechanism is a LOF partially with dominant-negative effects through functional deficits. LOF of KV7.5 channels will reduce the M-current, likely resulting in increased excitability of KV7.5-expressing neurons. Further studies on network level are necessary to understand which circuits are affected and how this induces generalized seizures. FUNDING: DFG/FNR Research Unit FOR-2715 (Germany/Luxemburg), BMBF rare disease network Treat-ION (Germany), foundation 'no epilep' (Germany).
- Published
- 2022
38. An online parenting intervention to prevent affective disorders in high-risk adolescents: the PIPA trial protocol
- Author
-
Connor, C, Yap, MBH, Warwick, J, Birchwood, M, De Valliere, N, Madan, J, Melvin, GA, Padfield, E, Patterson, P, Petrou, S, Raynes, K, Stewart-Brown, S, Thompson, A, Connor, C, Yap, MBH, Warwick, J, Birchwood, M, De Valliere, N, Madan, J, Melvin, GA, Padfield, E, Patterson, P, Petrou, S, Raynes, K, Stewart-Brown, S, and Thompson, A
- Abstract
BACKGROUND: Adolescent depression can place a young person at high risk of recurrence and a range of psychosocial and vocational impairments in adult life, highlighting the importance of early recognition and prevention. Parents/carers are well placed to notice changes in their child's emotional wellbeing which may indicate risk, and there is increasing evidence that modifiable factors exist within the family system that may help reduce the risk of depression and anxiety in an adolescent. A randomised controlled trial (RCT) of the online personalised 'Partners in Parenting' programme developed in Australia, focused on improving parenting skills, knowledge and awareness, showed that it helped reduce depressive symptoms in adolescents who had elevated symptom levels at baseline. We have adapted this programme and will conduct an RCT in a UK setting. METHODS: In total, 433 family dyads (parents/carers and children aged 11-15) will be recruited through schools, social media and parenting/family groups in the UK. Following completion of screening measures of their adolescent's depressive symptoms, parents/carers of those with elevated scores will be randomised to receive either the online personalised parenting programme or a series of online factsheets about adolescent development and wellbeing. The primary objective will be to test whether the personalised parenting intervention reduces depressive symptoms in adolescents deemed at high risk, using the parent-reported Short Mood & Feelings Questionnaire. Follow-up assessments will be undertaken at 6 and 15 months and a process evaluation will examine context, implementation and impact of the intervention. An economic evaluation will also be incorporated with cost-effectiveness of the parenting intervention expressed in terms of incremental cost per quality-adjusted life year gained. DISCUSSION: Half of mental health problems emerge before mid-adolescence and approximately three-quarters by mid-20s, highlighting the need
- Published
- 2022
39. Antisense oligonucleotide therapy for KCNT1 encephalopathy
- Author
-
Burbano, LE, Li, M, Jancovski, N, Jafar-Nejad, P, Richards, K, Sedo, A, Soriano, A, Rollo, B, Jia, L, V. Gazina, E, Piltz, S, Adikusuma, F, Thomas, PQ, Kopsidas, H, Rigo, F, Reid, CA, Maljevic, S, Petrou, S, Burbano, LE, Li, M, Jancovski, N, Jafar-Nejad, P, Richards, K, Sedo, A, Soriano, A, Rollo, B, Jia, L, V. Gazina, E, Piltz, S, Adikusuma, F, Thomas, PQ, Kopsidas, H, Rigo, F, Reid, CA, Maljevic, S, and Petrou, S
- Abstract
Developmental and epileptic encephalopathies (DEEs) are characterized by pharmaco-resistant seizures with concomitant intellectual disability. Epilepsy of infancy with migrating focal seizures (EIMFS) is one of the most severe of these syndromes. De novo variants in ion channels, including gain-of-function variants in KCNT1, which encodes for sodium activated potassium channel protein KNa1.1, have been found to play a major role in the etiology of EIMFS. Here, we test a potential precision therapeutic approach in KCNT1-associated DEE using a gene-silencing antisense oligonucleotide (ASO) approach. We generated a mouse model carrying the KCNT1 p.P924L pathogenic variant; only the homozygous animals presented with the frequent, debilitating seizures and developmental compromise that are seen in patients. After a single intracerebroventricular bolus injection of a Kcnt1 gapmer ASO in symptomatic mice at postnatal day 40, seizure frequency was significantly reduced, behavioral abnormalities improved, and overall survival was extended compared with mice treated with a control ASO (nonhybridizing sequence). ASO administration at neonatal age was also well tolerated and effective in controlling seizures and extending the life span of treated animals. The data presented here provide proof of concept for ASO-based gene silencing as a promising therapeutic approach in KCNT1-associated epilepsies.
- Published
- 2022
40. An online parenting intervention to prevent affective disorders in high-risk adolescents: the PIPA trial protocol (vol 23, 655, 2022)
- Author
-
Connor, C, Yap, MBH, Warwick, J, Birchwood, M, De Valliere, N, Madan, J, Melvin, GA, Padfeld, E, Patterson, P, Petrou, S, Raynes, K, Stewart-Brown, S, Thompson, A, Connor, C, Yap, MBH, Warwick, J, Birchwood, M, De Valliere, N, Madan, J, Melvin, GA, Padfeld, E, Patterson, P, Petrou, S, Raynes, K, Stewart-Brown, S, and Thompson, A
- Published
- 2022
41. MSR68 Development of a Checklist for Studies Reporting the Elicitation of Stated Preferences Values for Child Health Related Quality of Life
- Author
-
Bailey, C, Howell, M, Raghunandan, R, Dalziel, K, Howard, K, Mulhern, B, Petrou, S, Rowen, D, Salisbury, A, Viney, R, Lancsar, E, Devlin, N, Bailey, C, Howell, M, Raghunandan, R, Dalziel, K, Howard, K, Mulhern, B, Petrou, S, Rowen, D, Salisbury, A, Viney, R, Lancsar, E, and Devlin, N
- Published
- 2022
42. Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures.
- Author
-
Kwon, J, Freijser, L, Huynh, E, Howell, M, Chen, G, Khan, K, Daher, S, Roberts, N, Harrison, C, Smith, S, Devlin, N, Howard, K, Lancsar, E, Bailey, C, Craig, J, Dalziel, K, Hayes, A, Mulhern, B, Wong, G, Ratcliffe, J, Petrou, S, Kwon, J, Freijser, L, Huynh, E, Howell, M, Chen, G, Khan, K, Daher, S, Roberts, N, Harrison, C, Smith, S, Devlin, N, Howard, K, Lancsar, E, Bailey, C, Craig, J, Dalziel, K, Hayes, A, Mulhern, B, Wong, G, Ratcliffe, J, and Petrou, S
- Abstract
In the original version of this article, the author’s name Emily Lancsar was incorrectly written as Emily Lanscar. The original article has been corrected.
- Published
- 2022
43. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
- Author
-
Husereau, D, Drummond, M, Augustovski, F, de Bekker-Grob, E, Briggs, AH, Carswell, C, Caulley, L, Chaiyakunapruk, N, Greenberg, D, Loder, E, Mauskopf, J, Mullins, CD, Petrou, S, Pwu, R-F, Staniszewska, S, Jakab, I, Kinloch, E, Low, E, Mossman, J, Noone, D, Posner, P, Watson, J, Babidge, W, Beamesderfer, L, Beerens, D, Cryer, T, Donnelly, A, Espinoza, M, Greiner, W, Happe, L, Hiligsmann, M, Laine, C, Lee, L, Lee, K, Pafitis, N, Robinson, J, Stein, K, Szunyogova, E, Weber, W, Wrightson, T, Zikmund-Fisher, B, Aubin, M-C, Berger, M, Campbell, J, Coyle, D, Dyer, M, Edlin, R, al., Et, Health Technology Assessment (HTA), Epidemiology, Force, CHEERS 2022 ISPOR Good Research Practices Task, Virology, Radiology & Nuclear Medicine, and CHEERS 2022 ISPOR Good Research Practices Task Force
- Subjects
Research Report ,Economics and Econometrics ,Medicine (General) ,Technology Assessment, Biomedical ,Cost-Benefit Analysis ,Economics, Econometrics and Finance (miscellaneous) ,Pharmaceutical Science ,Guidelines as Topic ,Reporting guidance ,Pharmacy ,Guideline ,R5-920 ,SDG 3 - Good Health and Well-being ,Research Methods & Reporting ,Humans ,Pharmacology (medical) ,Health technology assessment ,Pharmacology ,Publishing ,Health Policy ,Public Health, Environmental and Occupational Health ,Obstetrics and Gynecology ,General Medicine ,R1 ,Economic evaluation ,Checklist ,Economics, Medical ,Research Design ,Costs and Cost Analysis ,Medicine ,Original Article ,Public aspects of medicine ,RA1-1270 ,Health economics ,Delivery of Health Care ,RA - Abstract
Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, as well as the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as health care, public health, education, social care, etc). This summary article presents the new CHEERS 2022 28-item checklist and recommendations for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer reviewed journals as well as the peer reviewers and editors assessing them for publication. However, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, as there is an increasing emphasis on transparency in decision making. Supplementary Information The online version contains supplementary material available at 10.1186/s12889-021-12491-0.
- Published
- 2022
44. Additional file 1 of An online parenting intervention to prevent affective disorders in high-risk adolescents: the PIPA trial protocol
- Author
-
Connor, C., Yap, M. B. H., Warwick, J., Birchwood, M., De Valliere, N, Madan, J., Melvin, G. A., Padfield, E., Patterson, P., Petrou, S., Raynes, K., Stewart-Brown, S., and Thompson, A.
- Abstract
Additional file 1. Trial information leaflets (for schools, parents/carers and young people) and trial poster.
- Published
- 2022
- Full Text
- View/download PDF
45. Additional file 4 of An online parenting intervention to prevent affective disorders in high-risk adolescents: the PIPA trial protocol
- Author
-
Connor, C., Yap, M. B. H., Warwick, J., Birchwood, M., De Valliere, N, Madan, J., Melvin, G. A., Padfield, E., Patterson, P., Petrou, S., Raynes, K., Stewart-Brown, S., and Thompson, A.
- Abstract
Additional file 4. Parent consent form and young person assent form.
- Published
- 2022
- Full Text
- View/download PDF
46. Association of ultra-rare coding variants with genetic generalized epilepsy: A case–control whole exome sequencing study
- Author
-
Koko, M., Motelow, J. E., Stanley, K. E., Bobbili, D. R., Dhindsa, R. S., May, P., Alldredge, B. K., Allen, A. S., Altmuller, J., Amrom, D., Andermann, E., Auce, P., Avbersek, A., Baulac, S., Bautista, J. F., Becker, F., Bellows, S. T., Berghuis, B., Berkovic, S. F., Bluvstein, J., Boro, A., Bridgers, J., Burgess, R., Caglayan, H., Cascino, G. D., Cavalleri, G. L., Chung, S. -K., Cieuta-Walti, C., Cloutier, V., Consalvo, D., Cossette, P., Crumrine, P., Delanty, N., Depondt, C., Desbiens, R., Devinsky, O., Dlugos, D., Epstein, M. P., Everett, K., Fiol, M., Fountain, N. B., Francis, B., French, J., Freyer, C., Friedman, D., Gambardella, A., Geller, E. B., Girard, S., Glauser, T., Glynn, S., Goldstein, D. B., Gravel, M., Haas, K., Haut, S. R., Heinzen, E. L., Helbig, I., Hildebrand, M. S., Johnson, M. R., Jorgensen, A., Joshi, S., Kanner, A., Kirsch, H. E., Klein, K. M., Knowlton, R. C., Koeleman, B. P. C., Kossoff, E. H., Krause, R., Krenn, M., Kunz, W. S., Kuzniecky, R., Langley, S. R., Leguern, E., Lehesjoki, A. -E., Lerche, H., Leu, C., Lortie, A., Lowenstein, D. H., Marson, A. G., Mebane, C., Mefford, H. C., Meloche, C., Moreau, C., Motika, P. V., Muhle, H., Moller, R. S., Nabbout, R., Nguyen, D. K., Nikanorova, M., Novotny, E. J., Nurnberg, P., Ottman, R., O'Brien, T. J., Paolicchi, J. M., Parent, J. M., Park, K., Peter, S., Petrou, S., Petrovski, S., Pickrell, W. O., Poduri, A., Radtke, R. A., Rees, M. I., Regan, B. M., Ren, Z., Sadleir, L. G., Sander, J. W., Sander, T., Scheffer, I. E., Schubert, J., Shellhaas, R. A., Sherr, E. H., Shih, J. J., Shinnar, S., Sills, G. J., Singh, R. K., Siren, A., Sirven, J., Sisodiya, S. M., Smith, M. C., Sonsma, A. C. M., Striano, P., Sullivan, J., Thio, L. L., Thomas, R. H., Venkat, A., Vining, E. P. G., Von Allmen, G. K., Wang, Q., Weber, Y. G., Weckhuysen, S., Weisenberg, J. L., Widdess-Walsh, P., Winawer, M. R., Wolking, S., Zara, F., Zimprich, F., Canadian Epilepsy Network, Epi4K Consortium, Epilepsy Phenome/Genome Project, EpiPGX Consortium, EuroEPINOMICS-CoGIE Consortium, Department of Medical and Clinical Genetics, Medicum, Fonds National de la Recherche - FnR [sponsor], Luxembourg Centre for Systems Biomedicine (LCSB): Bioinformatics Core (R. Schneider Group) [research center], Peter, Sarah, Petrou, Steven, Petrovski, Slavé, Pickrell, William O., Poduri, Annapurna, Radtke, Rodney A., Rees, Mark I., Regan, Brigid M., Ren, Zhong, Sadleir, Lynette G., Alldredge, Brian K., Sander, Josemir W., Sander, Thomas, Scheffer, Ingrid E., Schubert, Julian, Shellhaas, Renée A., Sherr, Elliott H., Shih, Jerry J., Shinnar, Shlomo, Sills, Graeme J., Singh, Rani K., Allen, Andrew S., Siren, Auli, Sirven, Joseph, Sisodiya, Sanjay M., Smith, Michael C., Sonsma, Anja C. M., Striano, Pasquale, Sullivan, Joseph, Thio, Liu Lin, Thomas, Rhys H., Venkat, Anu, Altmüller, Janine, Vining, Eileen P. G., Von Allmen, Gretchen K., Wang, Quanli, Weber, Yvonne G., Weckhuysen, Sarah, Weisenberg, Judith L., Widdess-Walsh, Peter, Winawer, Melodie R., Wolking, Stefan, Zara, Federico, Amrom, Dina, Zimprich, Fritz, Andermann, Eva, Auce, Pauls, Avbersek, Andreja, Baulac, Stéphanie, Bautista, Jocelyn F., Becker, Felicitas, Bellows, Susannah T., Berghuis, Bianca, Berkovic, Samuel F., Bluvstein, Judith, Boro, Alex, Bridgers, Joshua, Burgess, Rosemary, Caglayan, Hande, Cascino, Gregory D., Cavalleri, Gianpiero L., Chung, Seo-Kyung, Cieuta-Walti, Cécile, Cloutier, Véronique, Consalvo, Damian, Cossette, Patrick, Crumrine, Patricia, Delanty, Norman, Depondt, Chantal, Desbiens, Richard, Devinsky, Orrin, Dlugos, Dennis, Epstein, Michael P., Everett, Kate, Fiol, Miguel, Fountain, Nathan B., Francis, Ben, French, Jacqueline, Freyer, Catharine, Friedman, Daniel, Gambardella, Antonio, Geller, Eric B., Girard, Simon, Glauser, Tracy, Glynn, Simon, Goldstein, David B., Gravel, Micheline, Haas, Kevin, Haut, Sheryl R., Heinzen, Erin L., Helbig, Ingo, Hildebrand, Michael S., Johnson, Michael R., Jorgensen, Andrea, Joshi, Sucheta, Kanner, Andres, Kirsch, Heidi E., Klein, Karl M., Knowlton, Robert C., Koeleman, Bobby P. C., Kossoff, Eric H., Krause, Roland, Krenn, Martin, Kunz, Wolfram S., Kuzniecky, Ruben, Langley, Sarah R., LeGuern, Eric, Lehesjoki, Anna-Elina, Lerche, Holger, Leu, Costin, Lortie, Anne, Lowenstein, Daniel H., Marson, Anthony G., Mebane, Caroline, Mefford, Heather C., Meloche, Caroline, Moreau, Claudia, Motika, Paul V., Muhle, Hiltrud, Møller, Rikke S., Nabbout, Rima, Nguyen, Dang K., Nikanorova, Marina, Novotny, Edward J., Nürnberg, Peter, Ottman, Ruth, O'Brien, Terence J., Paolicchi, Juliann M., Parent, Jack M., and Park, Kristen
- Subjects
GABA receptors ,Neurology [D14] [Human health sciences] ,Clinical Sciences ,GABA(A) receptors ,GABRG2 ,familial epilepsy ,Article ,Clinical Research ,Receptors ,Exome Sequencing ,Genetics ,2.1 Biological and endogenous factors ,Humans ,GGE ,Genetic Predisposition to Disease ,sporadic epilepsy ,EpiPGX Consortium ,Aetiology ,gamma-Aminobutyric Acid ,GABAA receptors ,Epi4K Consortium ,Epilepsy ,Neurology & Neurosurgery ,Neurologie [D14] [Sciences de la santé humaine] ,Generalized ,GABA-A ,Prevention ,Human Genome ,Neurosciences ,1184 Genetics, developmental biology, physiology ,3112 Neurosciences ,Receptors, GABA-A ,EuroEPINOMICS-CoGIE Consortium ,Neurology ,Case-Control Studies ,Epilepsy, Generalized ,Canadian Epilepsy Network ,Neurology (clinical) ,Genetics & genetic processes [F10] [Life sciences] ,3111 Biomedicine ,Human medicine ,Génétique & processus génétiques [F10] [Sciences du vivant] ,Epilepsy Phenome/Genome Project - Abstract
ObjectiveWe aimed to identify genes associated with genetic generalized epilepsy (GGE) by combining large cohorts enriched with individuals with a positive family history. Secondarily, we set out to compare the association of genes independently with familial and sporadic GGE.MethodsWe performed a case-control whole exome sequencing study in unrelated individuals of European descent diagnosed with GGE (previously recruited and sequenced through multiple international collaborations) and ancestry-matched controls. The association of ultra-rare variants (URVs; in 18834 protein-coding genes) with epilepsy was examined in 1928 individuals with GGE (vs. 8578 controls), then separately in 945 individuals with familial GGE (vs. 8626 controls), and finally in 1005 individuals with sporadic GGE (vs. 8621 controls). We additionally examined the association of URVs with familial and sporadic GGE in two gene sets important for inhibitory signaling (19genes encoding γ-aminobutyric acid type A [GABAA ] receptors, 113genes representing the GABAergic pathway).ResultsGABRG2 was associated with GGE (p=1.8×10-5 ), approaching study-wide significance in familial GGE (p=3.0×10-6 ), whereas no gene approached a significant association with sporadic GGE. Deleterious URVs in the most intolerant subgenic regions in genes encoding GABAA receptors were associated with familial GGE (odds ratio [OR]=3.9, 95% confidence interval [CI]=1.9-7.8, false discovery rate [FDR]-adjusted p=.0024), whereas their association with sporadic GGE had marginally lower odds (OR=3.1, 95% CI=1.3-6.7, FDR-adjusted p=.022). URVs in GABAergic pathway genes were associated with familial GGE (OR=1.8, 95% CI=1.3-2.5, FDR-adjusted p=.0024) but not with sporadic GGE (OR=1.3, 95% CI=.9-1.9, FDR-adjusted p=.19).SignificanceURVs in GABRG2 are likely an important risk factor for familial GGE. The association of gene sets of GABAergic signaling with familial GGE is more prominent than with sporadic GGE.
- Published
- 2022
47. Additional file 2 of An online parenting intervention to prevent affective disorders in high-risk adolescents: the PIPA trial protocol
- Author
-
Connor, C., Yap, M. B. H., Warwick, J., Birchwood, M., De Valliere, N, Madan, J., Melvin, G. A., Padfield, E., Patterson, P., Petrou, S., Raynes, K., Stewart-Brown, S., and Thompson, A.
- Abstract
Additional file 2. Process evaluation focus group question frameworks.
- Published
- 2022
- Full Text
- View/download PDF
48. Additional file 3 of An online parenting intervention to prevent affective disorders in high-risk adolescents: the PIPA trial protocol
- Author
-
Connor, C., MBH, Yap, Warwick, J., Birchwood, M., De Valliere, N, Madan, J., Melvin, G. A., Padfield, E., Patterson, P., Petrou, S., Raynes, K., Stewart-Brown, S., and Thompson, A.
- Abstract
Additional file 3. Process evaluation family interview question framework.
- Published
- 2022
- Full Text
- View/download PDF
49. Early Positive Approaches to Support (E-PAtS) for families of young children with intellectual disability: A Feasibility Randomised Controlled Trial
- Author
-
Coulman, E., Gore, N., Moody, G., Wright, M., Segrott, J., Gillespie, D., Petrou, S., Sungwok, K., Bradshaw, J., McNamara, R., Jahoda, A., Lindsay, G., Shurlock, J., Totsika, V., Stanford, C., Carter, A, Barlow, C., and Hastings, R.
- Subjects
BF - Abstract
Background: Parents of children with intellectual disabilities are likely to experience poorer mental wellbeing and face challenges accessing support. Early Positive Approaches to Support (E-PAtS) is a group-based programme, co-produced with parents and professionals, based on existing research evidence and a developmental systems approach to support parental mental wellbeing. The aim of this study was to assess the feasibility of community service provider organisations delivering E-PAtS to parents/family caregivers of young children with intellectual disability, to inform a potential definitive randomised controlled trial of the effectiveness and cost-effectiveness of E-PAtS.\ud Methods: This study was a feasibility cluster randomised controlled trial, with embedded process evaluation. Up to two parents/family caregivers of a child (18 months to less than 6 years old) with intellectual disability were recruited at research sites and allocated to intervention (E-PAtS and usual practice) or control (usual practice) on a 1:1 basis at cluster (family) level. Data were collected at baseline and three and 12 months’ post-randomisation. The following feasibility outcomes were assessed: participant recruitment rates and effectiveness of recruitment pathways; retention rates; intervention adherence and fidelity; service provider recruitment rates and willingness to participate in a future trial; barriers and facilitating factors for recruitment, engagement, and intervention delivery; and feasibility of collecting outcome measures.\ud Results: Seventy-four families were randomised to intervention or control (n=37). Retention rates were 72% at 12 months post-randomisation, and completion of the proposed primary outcome measure (WEMWBS) was 51%. Recruitment of service provider organisations and facilitators was feasible and intervention implementation acceptable. Adherence to the intervention was 76% and the intervention was well-received by participants; exploratory analyses suggest that adherence and attendance may be associated with improved wellbeing. Health economic outcome measures were collected successfully and evidence indicates that linkage with routine data would be feasible in a future trial.\ud Conclusions: The E-PAtS Feasibility RCT has demonstrated that the research design and methods of intervention implementation are generally feasible. Consideration of the limitations of this feasibility trial and any barriers to conducting a future definitive trial, do however, need to be considered by researchers.
- Published
- 2021
50. Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
- Author
-
Kwon, J, Freijser, L, Huynh, E, Howell, M, Chen, G, Khan, K, Daher, S, Roberts, N, Harrison, C, Smith, S, Devlin, N, Howard, K, Lanscar, E, Bailey, C, Craig, J, Dalziel, K, Hayes, A, Mulhern, B, Wong, G, Ratcliffe, J, and Petrou, S
- Subjects
Pharmacology ,Parents ,Adolescent ,Health Policy ,Health Status ,Public Health, Environmental and Occupational Health ,Infant ,Surveys and Questionnaires ,Health Policy & Services ,Quality of Life ,Drugs, Generic ,Humans ,Patient Reported Outcome Measures ,Child ,11 Medical and Health Sciences, 14 Economics - Abstract
Background and Aims Patient-reported outcome measures (PROMs) for children (aged ≤ 18 years) present methodological challenges. PROMs can be categorised by their diverse underlying conceptual bases, including functional, disability and health (FDH) status; quality of life (QoL); and health-related quality of life (HRQoL). Some PROMs are designed to be accompanied by preference weights. PROMs should account for childhood developmental differences by incorporating age-appropriate health/QoL domains, guidance on respondent type(s) and design. This systematic review aims to identify generic multidimensional childhood PROMs and synthesise their characteristics by conceptual basis, target age, measurement considerations, and the preference-based value sets that accompany them. Methods The study protocol was registered in the Prospective Register of Systematic Reviews (CRD42021230833), and reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We conducted systematic database searches for generic multidimensional childhood PROMs covering the period 2012–2020, which we combined with published PROMs identified by an earlier systematic review that covered the period 1992–2011. A second systematic database search identified preference-based value sets for generic multidimensional PROMs. The PROMs were categorised by conceptual basis (FDH status, QoL and HRQoL) and by target age (namely infants and pre-schoolers aged < 5 years, pre-adolescents aged 5–11, adolescents aged 12–18 and multi-age group coverage). Descriptive statistics assessed how PROM characteristics (domain coverage, respondent type and design) varied by conceptual basis and age categories. Involvement of children in PROM development and testing was assessed to understand content validity. Characteristics of value sets available for the childhood generic multidimensional PROMs were identified and compared. Results We identified 89 PROMs, including 110 versions: 52 FDH, 29 QoL, 12 HRQoL, nine QoL-FDH and eight HRQoL-FDH measures; 20 targeted infants and pre-schoolers, 29 pre-adolescents, 24 adolescents and 37 for multiple age groups. Domain coverage demonstrated development trajectories from observable FDH aspects in infancy through to personal independence and relationships during adolescence. PROMs targeting younger children relied more on informant report, were shorter and had fewer ordinal scale points. One-third of PROMs were developed following qualitative research or surveys with children or parents for concept elicitation. There were 21 preference-based value sets developed by 19 studies of ten generic multidimensional childhood PROMs: seven were based on adolescents’ stated preferences, seven were from adults from the perspective of or on behalf of the child, and seven were from adults adopting an adult’s perspective. Diverse preference elicitation methods were used to elicit values. Practices with respect to anchoring values on the utility scale also varied considerably. The range and distribution of values reflect these differences, resulting in value sets with notably different properties. Conclusion Identification and categorisation of generic multidimensional childhood PROMs and value sets by this review can aid the development, selection and interpretation of appropriate measures for clinical and population research and cost-effectiveness-based decision-making.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.